Ebpay生命医药出版社

Ebpay生命

102494

论文已发表

提 交 论 文


注册即可获取Ebpay生命的最新动态

注 册



IF 收录期刊



  • 3.3 Breast Cancer (Dove Med Press)
  • 3.4 Clin Epidemiol
  • 2.5 Cancer Manag Res
  • 2.9 Infect Drug Resist
  • 3.5 Clin Interv Aging
  • 4.7 Drug Des Dev Ther
  • 2.7 Int J Chronic Obstr
  • 6.6 Int J Nanomed
  • 2.5 Int J Women's Health
  • 2.5 Neuropsych Dis Treat
  • 2.7 OncoTargets Ther
  • 2.0 Patient Prefer Adher
  • 2.3 Ther Clin Risk Manag
  • 2.5 J Pain Res
  • 2.8 Diabet Metab Synd Ob
  • 2.8 Psychol Res Behav Ma
  • 3.0 Nat Sci Sleep
  • 1.8 Pharmgenomics Pers Med
  • 2.7 Risk Manag Healthc Policy
  • 4.2 J Inflamm Res
  • 2.1 Int J Gen Med
  • 4.2 J Hepatocell Carcinoma
  • 3.7 J Asthma Allergy
  • 1.9 Clin Cosmet Investig Dermatol
  • 2.7 J Multidiscip Healthc



更多详情 >>





已发表论文

在“全员治疗”时代新诊断出的艾滋病患者中晚期艾滋病的患病率、危险因素及临床结局:来自中国西安市的一项回顾性队列研究

 

Authors Jin J, Pan S, Chen J, Yin J, Ba H, Hou H, Zhang Y, Ma K

Received 22 January 2025

Accepted for publication 5 May 2025

Published 9 May 2025 Volume 2025:18 Pages 2427—2438

DOI http://doi.org/10.2147/IDR.S518809

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Oliver Planz

Juan Jin,1,* Songnan Pan,2,* Jie Chen,1 Jinling Yin,1 Huanhuan Ba,1 Haohua Hou,1 Yuan Zhang,1 Kangxiao Ma1 

1Department of Infectious Diseases, Xi’an Eighth’s Hospital, Xi’an, Shaanxi, People’s Republic of China; 2Department of Infectious Diseases, Infectious Disease Hospital of Heilongjiang Province, Harbin, Heilongjiang, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Kangxiao Ma, Department of Infectious Diseases, Xi’an Eighth’s Hospital, 2 Zhangba East Road, Yanta District, Xi’an, Shaanxi, 710061, People’s Republic of China, Tel/Fax +86 029 85393973, Email kbdmzjj@163.com

Purpose: China launched “treat-all” in 2016 to make all HIV-positive people eligible for ART regardless of disease stage. Widespread treatment may not eliminate advanced HIV. This study investigated the prevalence, characteristics, risk factors, and clinical outcomes of advanced HIV disease (AHD) in newly diagnosed HIV-positive individuals in China during the “treat-all” period.
Patients and methods: We performed a retrospective cohort study on newly diagnosed adult ART-naive people with HIV (PWH) in Xi’an from 2016 to 2022. The prevalence of AHD and six-month mortality/loss to follow-up (LTFU) were investigated. Risk variables for AHD and predictors of mortality or LTFU in the cohort were investigated using multivariate logistic and Cox regression, respectively.
Results: Of the PWH, 47.5% (2999/6318) had AHD at HIV diagnosis. At enrollment, being ≥ 50 years (aOR: 1.75, 95% CI: 1.44– 2.12, P < 0.001; ≥ 50 vs 18– 29), 30– 49 years (aOR: 1.43, 95% CI: 1.24– 1.65, P < 0.001; 30– 49 vs 18– 29), opportunity infections (aOR: 7.43, 95% CI: 5.96– 9.35, P < 0.001), severe anemia (aOR: 3.56, 95% CI: 1.81– 7.70, P = 0.001) and liver disease (aOR: 3.09, 95% CI: 1.48– 7.05, P = 0.004) were independently associated with AHD. Within 6 months of enrollment, 95.6% and 58.3% of those who died or were LTFU had AHD. AHD (aHR: 14.30, 95% CI: 4.42– 46.30, P < 0.001), ≥ 50 years (aHR: 5.39, 95% CI: 2.10– 13.82, P < 0.001; ≥ 50 years vs 18– 29 years), those with opportunistic infections (aHR: 2.59, 95% CI: 1.54– 4.34, P < 0.001), and severe anemia (aHR: 9.89, 95% CI: 5.19– 18.87, P < 0.001) were independent predictors of six-month mortality.
Conclusion: Under the “treat-all” policy, Xi’an had a high prevalence of AHD upon HIV diagnosis. AHD predicted 6-month mortality. Urgent implementation of targeted strategies is necessary to minimize AHD.

Keywords: advanced HIV disease, HIV, mortality, loss to follow-up, treat all, China

Download Article[PDF]